Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Approved for marketing 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Lymphoid 2

Conditions

Osteosarcoma 6Lymphoma 4Renal Insufficiency 3Neurotoxicity Syndromes 2Neoplasms 2Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Hematologic Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Water Intoxication 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Acute Kidney Injury 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 6Lenalidomide 5pomalidomide 3isatuximab 3glucarpidase 3Kidney Transplantation 3Calcium Dobesilate 3Thalidomide 2Paclitaxel 2Gemcitabine 2Carboplatin 2Blood Specimen Collection 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Renal Insufficiency × glucarpidase × Clear all
NCT00634504 2022-06-06

LVPK

BTG International Inc.

Phase 1 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Osteosarcoma, Renal Insufficiency

NCT00219791 2014-09-11

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

BTG International Inc.

Phase 2 Completed

Neoplasms, Renal Insufficiency

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡